symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
EVLO,1.2,1.666436,523325,22602120,0,0.48-48.0,-1.71,"Evelo Biosciences, Inc.",USD,0001694665,US2997341035,299734103,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.evelobio.com,"Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Dr. Balkrishan  Gill Ph.D.,Healthcare,US,66,617 577 0300,620 Memorial Drive,Cambridge,MA,02139,2.5536,3.5936,https://financialmodelingprep.com/image-stock/EVLO.png,2018-05-08,False,False,True,False,False
